Promising drug cocktail eyed for Tough-to-Treat urinary cancer
NCT ID NCT07633353
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how well a combination of two drugs (enfortumab vedotin and pembrolizumab) works as a first treatment for people with advanced upper tract urothelial carcinoma, a rare cancer of the urinary tract. Researchers will track 50 patients in France to see how many respond to treatment and how long they live without the cancer growing. They will also check for side effects and look at certain markers in the tumors that might predict who benefits most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- enfortumab vedotin plus pembrolizumab
- What this could lead to
- If successful, this could confirm that the drug combination is an effective first-line treatment for this rare type of urinary tract cancer.
- What could go wrong
- This is a small, observational study (50 patients) with no control group, so results may not be definitive. Side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Hospitalier Universitaire
Nîmes, 30000, France